Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Cytarabine and 213Bi-lintuzumab in Advanced Myeloid Malignancies
NCT00014495Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2000
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 213Bi-lintuzumab in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2000; status: completed.
02
Drugs
213Bi-lintuzumab
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00014495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014495.